Changing the Face of Cardiovascular Disease in Diabetes
Course expires: 01/31/2020
This online enduring material is a reproduction of the live session that was held at the 2018 AACE Annual Meeting in Boston, MA.
- Examine data on CV risk in diabetes
- Discuss the ways that newer antidiabetic drugs that reduce CV events and mortality are changing current approaches to diabetes management
- Integrate CV-reducing agents into individualized diabetes therapy, as recommended in current guidelines
All physicians and allied health professionals interested in the study, diagnosis, and treatment of endocrine-related diseases.
The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of .75 AMA PRA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.